Here's Why Grail Stock Soared Higher This Week
Shares in multi-cancer early detection (MCED) test company Grail (NASDAQ: GRAL) rose by 11.4% in the week to Thursday, 1 p.m. The move comes as analysts warm to the stock's risk/reward proposition.
High risk and high reward are definitely how investors should think about this stock. The stock declined sharply in February on news that it missed its primary endpoint in a 3-year period and in a 142,000-person demographic trial of its Galleri MCED test with England's National Health Service.
Image source: Getty Images.
Source Fool.com
